Redhill Biopharma Ltd. current report, Q2 FY2020

Redhill Biopharma Ltd. Form 6-K Summary

Business Context and Reporting Period

This Form 6-K reports on the Annual General Meeting of Shareholders held on May 4, 2020. Redhill Biopharma Ltd. is a foreign private issuer based in Tel Aviv, Israel, filing under Form 20-F.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance resolutions and does not contain financial statements or performance data for the period.

Material Changes

Significant corporate governance changes were approved by shareholders, including:

  • Leadership Appointment: Dror Ben-Asher was approved to serve as Chairman of the Board and Chief Executive Officer.
  • Board Composition: Re-election of Rick D. Scruggs; election of Dr. Shmuel Cabilly and Mr. Giuseppe Cipriano for three-year terms.
  • Auditor Appointment: Kesselman & Kesselman (PwC network) appointed as auditors for 2020.
  • Capital Structure: Approval of an increase in authorized share capital.

Guidance, Outlook, and Compensation Actions

The filing contains no financial guidance, outlook, or management commentary regarding future business performance. However, several material compensation and equity actions were approved:

  • Amendments to the Compensation Policy and the Amended and Restated Award Plan (2010).
  • Grant of options to purchase American Depository Shares (ADSs) to non-executive directors, Dror Ben-Asher, and Rick D. Scruggs.
  • Extension and repricing of existing options granted to directors and Dror Ben-Asher.
  • Revision of compensation terms for Rick D. Scruggs, Chief Commercial Officer.

Key Facts for Investor Verification

  • Verify the specific terms of the option repricing and extensions, as these may impact dilution.
  • Confirm the details of the increased authorized share capital.
  • Review the full text of the amended Compensation Policy and Award Plan for changes to executive incentives.
  • Check subsequent filings for the financial impact of the new leadership structure under Dror Ben-Asher.